The FDA is already under fire from lawmakers for recent delays and rejections of new drugs for rare diseases.

Choose St. Louis Business Journal as a preferred news source to see more of our reporting on Google. Laboratory real estate ...

MAHA brings chaos to biotech investment; Measles cases surge and threaten Trump vaccine policy changes; Autism scientists form independent group.

Q4 2025 . Management View. CEO Ofer Haviv emphasized a strategic transformation, stating Evogene "made deliberate choice to sharpen our ...

Vertex's CF drugs are bringing in billions of dollars in revenue, and in recent years the company has also expanded into ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

As the pressure of food and nutrition security conflicts directly with disrupting the ocean ecosystem, insects can power a ...

Spyre Therapeutics CEO Cameron Turtle talks about the search for an IBD treatment on this week's "The Readout LOUD." ...

BioTechnique broadens capabilities with end‑to‑end fill‑finish, advanced lyophilization development, and integrated ...

Drug-pricing promises are colliding with reality: A month in, the TrumpRx platform still includes only a limited number of drugs and it’s unclear if the site is being widely used, STAT’s Daniel Payne ...

Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX.